News

ASCO: Stop Underdosing Obese Cancer Patients


 

FROM THE JOURNAL OF CLINICAL ONCOLOGY

"While chemotherapy dose for an obese patient may be larger than some physicians are accustomed to, they can rest assured that the risk of toxicity associated with chemotherapy dosing based on actual body weight is no greater in obese patients than in nonobese patients with cancer," said Dr. Lyman, a professor of medicine in the division of medical oncology at Duke University, Durham, N.C.

The full practice guideline, along with additional information on methodology and clinical resources, is available at ASCO’s website. For additional patient information, click here.

No financial conflicts of interest were reported.

Pages

Recommended Reading

ACOG Releases Guideline for Breast Cancer Management
Breast Cancer ICYMI
VEGF-Targeting Cancer Drugs Raise Risk of Fatal Side Effects
Breast Cancer ICYMI
Estrogen Protects Against Breast Cancer Long After Treatment
Breast Cancer ICYMI
Identify Depressive Symptoms Early in Breast Cancer Patients
Breast Cancer ICYMI
Therapeutic optimization of aromatase inhibitor–associated arthralgia: etiology, onset, resolution, and symptom management in early breast cancer
Breast Cancer ICYMI
The Role of Spirituality and Religious Coping in the Quality of Life of Patients With Advanced Cancer Receiving Palliative Radiation Therapy
Breast Cancer ICYMI
Community Oncology Podcast - HER2-positive metastatic breast cancer
Breast Cancer ICYMI
Neoadjuvant Anastrozole, Other AIs Lower Mastectomy Rate
Breast Cancer ICYMI
Some Triple-Negative Breast Cancers Express Androgen Receptor
Breast Cancer ICYMI
Estrogen-Only HT Also Increases Breast Cancer Risk
Breast Cancer ICYMI